Antitrust: Commission opens formal investigation into possible anticompetitive conduct of Teva in relation to a blockbuster multiple sclerosis medicine

(Credit: Unsplash)

This article is brought to you in association with the European Commission.


The European Commission has opened a formal antitrust investigation to assess whether the pharmaceutical company Teva has illegally delayed the market entry and uptake of medicines that compete with its blockbuster multiple sclerosis drug Copaxone. The Commission will investigate whether Teva has abused a dominant market position in breach of EU antitrust rules.

Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “Multiple sclerosis is a chronic illness affecting the daily lives of more than half a million Europeans requiring life-long treatment. Despite great efforts of the scientific community, humanity has not yet found a treatment for this disease, which remains incurable. It is therefore paramount to preserve healthy competition in the market for available drugs that aim at slowing down the disease and improving patients’ quality of life. It is also important that companies compete to innovate so that new and affordable treatments can emerge. Today, we have decided to launch an in-depth investigation into whether Teva may have abusively blocked or delayed the market entry of competitors to its blockbuster drug Copaxone, to the detriment of patients and health systems”.

Copaxone, Teva’s best selling drug, is widely used for the treatment of relapsing forms of multiple sclerosis and contains the active pharmaceutical ingredient glatiramer acetate.

In 2015, Teva’s basic patent covering glatiramer acetate expired. The Commission will investigate whether, following the patent expiry, Teva may have artificially extended the market exclusivity of Copaxone by strategically filing and withdrawing divisional patents, repeatedly delaying entry of its generic competitor who was obliged to file a new legal challenge each time. Divisional patents originate from a broader “parent” patent and may cover significantly overlapping inventions, sometimes allowing the patentee to multiply the patent barriers that a generic competitor needs to overcome to enter the market.

In addition, the Commission will also examine whether Teva may have pursued a communication campaign to unduly hinder the use of competing glatiramer acetate products. The Commission has indications that Teva’s campaign, primarily directed at healthcare institutions and professionals, may have targeted competing products to create a false perception of health risks associated with their use, even following the approval of these medicines by competent public health authorities.

If proven, Teva’s behaviour may amount to an abuse of dominant position and infringe Article 102 of the Treaty on the Functioning of the European Union (TFEU) and Article 54 of the European Economic Area (EEA) Agreement.

This is the Commission’s first formal investigation into potential abuses relating to the misuse of patent procedures and exclusionary disparagement of competing products in the pharmaceutical industry.

The Commission will now carry out its in-depth investigation as a matter of priority. The opening of formal proceedings does not prejudge the outcome of the investigation.

Background

Teva is a global pharmaceutical company headquartered in Israel and operating from several subsidiaries in the EEA.

The Commission carried out unannounced inspections at the premises of a number of Teva subsidiaries in the EEA in October 2019, followed by continued inspections at the Commission’s premises in Brussels in January 2020.

Market players have repeatedly pointed at alleged misuses of patent procedures and alleged exclusionary disparagement as important barriers to the entry of generic or biosimilar medicines.

Article 102 of the Treaty of the Functioning of the EU prohibits the abuse of dominant market positions. The implementation of these provisions is defined in the EU’s Antitrust Regulation (Council Regulation No 1/2003), which is also applied by national competition authorities.

Article 11(6) of the Antitrust Regulation provides that the opening of proceedings by the Commission relieves the competition authorities of the Member States of their competence to also apply EU competition rules to the practices concerned. Article 16(1) further provides that national courts must avoid adopting decisions which would conflict with a decision contemplated by the Commission in proceedings it has initiated.

The Commission has informed Teva and the competition authorities of the Member States that it has opened proceedings in this case.

There is no legal deadline for bringing an antitrust investigation to an end. The duration of an antitrust investigation depends on a number of factors, including the complexity of the case, the extent to which the companies concerned cooperate with the Commission and the exercise of the rights of defence.

More information on this investigation will be available on the Commission’s competition website, in the public case register under the case number AT.40588.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

How COVID-19 is throttling vital migration flows

UN rights chief Bachelet appeals for dialogue in Sudan amid reports ‘70 killed’ in demonstrations

Asian and Pacific economies: decreases in tax revenue highlight need to broaden tax bases

Coronavirus: harmonised standards for medical devices to respond to urgent needs

Turkey: Extension of EU humanitarian programmes supporting 1.7 million refugees receives green light

Health services for Syrian women caught up in war, foster safety and hope: UNFPA

ILO: Progress on gender equality at work remains inadequate

EU plans to exploit the Mediterranean Sea and the wealth beneath it

An entrepreneurial point-of view on tackling the migration crisis and the risks of abolishing Schengen

So, what is your favourite Sustainable Development Goal?

Three ways to improve your corporate culture in the #MeToo era

Social inclusion: how much should young people hope from the EU? 

Athens urged to fast track asylum seekers amid island shelters crisis – UNHCR

Vaccination: understanding the challenges surrounding COVID-19 vaccination campaigns

What India’s route to universal health coverage can teach the world

To what extent are our moral standards responsible for killing people?

5 amazing schools that will make you wish you were young again

How to describe chronic pain beyond numbers? A Brazilian measuring instrument

Security Council must ‘come together’ to address the plight of children trapped in armed conflict, says UN envoy

Mental health as a tool of survival at the Pandemic

European Youth calls on European Council for urgent action on “humanitarian crisis” and questions the EU/Turkey deal respect of human rights

Future EU financing and recovery: MEPs to assess summit outcome

When will Eurozone’s unemployment rate stop being Europe’s worst nightmare?

Mobile World Congress 2015 first to debate EU’s new stance on Net Neutrality and Roaming Charges

Afghanistan: UN mission welcomes new polling dates following election delays

Fairness should be at the heart of the agricultural goods trade

Vaccination: understanding the challenges surrounding COVID-19 vaccination campaigns

A Sting Exclusive: “The Digital Economy and Industry are no longer opposing terms”, Commissioner Oettinger underlines live from European Business Summit 2015

Tiny Iceland teaches the West how to treat bankers

Women’s rights and how medical students can act as aides of progressive change

The results of Finland’s basic income experiment are in. Is it working?

We can decide to live within the limits of our planet

Promoting Health in the Brazilian Amazon: one nation but many cultures

ECB money bonanza not enough to revive euro area, Germany longs to rule with stagnation

New EU rules ensure better protection for 120 million holidaymakers this summer

EU Migrant Crisis: Italian Coast Guard Headquarters and Italian Navy to give host national opening addresses at Border Security 2016 in Rome

UN chief pays tribute to Egypt’s role in avoiding ‘dramatic’ escalation in conflict across the Gaza-Israel border

ACP-EU : Agreement on climate change, migration and post-Cotonou

CO2 can be a valuable raw material, not just a climate killer. Here’s how

Scientists have created biodegradable microneedles to fight eye disease

Annual UN women activists’ summit opens with focus on services, infrastructure

How start-ups will lead India through the Fourth Industrial Revolution

EU Ombudsman investigates the European Commission

EU and UK soon to be in a post-Brexit rush over free trade agreement with Australia

Commission and EIB provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing

Could entrepreneurship be the real cure against the side effects of Brexit?

Rebuilding after COVID: The challenge is digital

Medical students: catalysts to close the gender gap

How the world can ‘reset’ itself after COVID-19 – according to these experts

Threat to biodiversity risks a flood of economic ruin

One third of poorer countries face both undernutrition and obesity: WHO report

State aid: Commission approves €900 million Slovenian scheme to support uncovered fixed costs of companies affected by coronavirus outbreak

Google case: A turning point in competition rules enforcement

Australia’s bushfires have pumped out half a year’s CO2 emissions

How Eurozone consumers spend their income when they have one…

25 years after population conference, women still face challenges to ‘well-being and human rights’, says UN chief

Cheese energy could power hundreds of UK homes

5G: How a ‘legion of robots’ could help save the rhino

The European Parliament fails to really restrict the rating agencies

Sponsored content: when QUALITY meets OPEX in manufacturing

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s